MAIN MENU
QUICK LINKS
CONNECT WITH US

Button
Coronavirus (COVID-19) updates, visitor restrictions and resources →

Clinical Trial Details

Title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Exploring the Efficacy, Safety, and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects with Drug-Resistant Focal Epilepsy
Study Description

The main purpose of this study is to see how well natalizumab (referred to from now on as the “study drug”) works in subjects with focal epilepsy (when seizures start in a region of the brain). Subjects who participate in this study will have seizures that did not fully improve and still occur frequently after taking 2 or more anti-epileptic drugs (AEDs). This study will see if the number of seizures the subject experiences decrease while taking the study drug and how safe the study drug is. The study drug will be given as an additional therapy alongside the subjects’ usual AEDs.

Investigators

Principal Investigator
Ramon E. Bautista, M.D., M.B.A.
Neurology

Sub Investigator
Suparna R. Krishnaiengar, M.B.B.S. (M.D.)
Neurology